Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Cardiovascular Medicine
Published in: Current Treatment Options in Cardiovascular Medicine 5/2024

02-04-2024 | Prostate Cancer | Review

Understanding Cardiovascular Risk in Prostate Cancer: Role of Disparities, Diabetes, and Aging

Authors: Priyanshu Nain, MD, Lakshya Seth, BA, Vraj Patel, BS, Stephanie Jiang, BS, Gaurav Gopu, BS, Rishabh Singh, MD, Nickolas Stabellini, BS, Ritu Reddy, BS, Neal L. Weintraub, MD, Ryan A. Harris, PhD, Jennifer Cullen, PhD, MPH, Neeraj Agarwal, MD, Justin Xavier Moore, PhD, MPH, Nazish Sayed, MD, PhD, Avirup Guha, MD, MPH

Published in: Current Treatment Options in Cardiovascular Medicine | Issue 5/2024

Login to get access

Abstract

Purpose of review

The primary objective of this review article is to dissect the intricate relationship between disparities, aging, diabetes, and their collective influence on cardiovascular disease (CVD) risk in prostate cancer (PC) patients. We sought to answer how these determinants interact with each other and contribute to the varying CVD outcomes observed in different subsets of PC patients.

Recent findings

It has become evident that social determinants of health (SDOH) significantly impact PC outcomes. Particularly, cardiovascular outcomes in non-Hispanic Black (NHB) patients, those from lower socioeconomic backgrounds, and residing in rural areas are notably worse. Diabetes, a growing concern worldwide, has been linked to increased PC-specific and all-cause mortality. Interestingly, recent studies highlight the potential of metformin therapy in enhancing survival rates, especially pivotal for those undergoing androgen deprivation therapy (ADT). Furthermore, the implications of age on PC are profound. The age-driven alterations in factors like allostatic load, responses to ADT, and vascular health play a crucial role in influencing CVD outcomes.

Summary

Our article highlights the multifaceted factors influencing cardiovascular risk in PC patients. Social disparities, aging, and diabetes mellitus significantly shape CVD outcomes. A holistic approach that targets both systemic and individual concerns, focusing on bridging healthcare access gaps and devising effective diabetes management strategies, is imperative. Metformin therapy emerges as a beacon of hope, especially for those patients on ADT. To improve cardiovascular outcomes in PC patients, there is an urgent need to target modifiable risk factors, emphasizing special attention to vulnerable populations. Further research is still needed to develop targeted interventions to mitigate the risk of disparities while improving cardiovascular outcomes, especially in vulnerable populations.
Literature
1.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.PubMedCrossRef
2.
Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, Pilie P, Sonbol MB, Alhalabi O. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4: e2119568.PubMedPubMedCentralCrossRef
3.
Ye Y, Zheng Y, Miao Q, Ruan H, Zhang X. Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol. 2022;12: 914875.PubMedPubMedCentralCrossRef
4.
5.
6.
7.
8.
Swaby J, Aggarwal A, Batra A, et al. Association of androgen deprivation therapy with metabolic disease in prostate cancer patients: an updated meta-analysis. Clin Genitourin Cancer. 2023;21:e182–9.PubMedCrossRef
9.
Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis. J Diabetes Investig. 2016;7:629–36.PubMedPubMedCentralCrossRef
10.
Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS ONE. 2015;10: e0117344.PubMedPubMedCentralCrossRef
11.
12.
Iyer HS, Gomez SL, Chen JT, Trinh Q, Rebbeck TR. Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: race and neighborhood socioeconomic position. Cancer. 2021;127:2525–34.PubMedCrossRef
13.
Nikita N, Banks J, Keith S, Yamoah K, Naik UP, Kim FJ, Shipon DM, Kelly WK, Rebbeck TR, Yao GL. Abstract 780: Racial disparities in death from cardiovascular disease for patients with prostate cancer: a population-based study. Cancer Res. 2021;81:780–780.CrossRef
14.
15.
The Lancet null. Syndemics: health in context. Lancet Lond Engl. 2017;389:881.CrossRef
16.
Hinata N, Fujisawa M. Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview. World J Mens Health. 2022;40:217.PubMedPubMedCentralCrossRef
17.
Vince RA, Jiang R, Bank M, et al. Evaluation of social determinants of health and prostate cancer outcomes among Black and White patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;6: e2250416.PubMedPubMedCentralCrossRef
18.
19.
Kovtun KA, Chen M-H, Braccioforte MH, Moran BJ, D’Amico AV. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer: Race and Risk of Death in Men With PC. Cancer. 2016;122:3608–14.PubMedCrossRef
20.
21.
Wu I, Modlin CS. Disparities in prostate cancer in African American men: what primary care physicians can do. Cleve Clin J Med. 2012;79:313–20.PubMedCrossRef
22.
Xie Z, St Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS ONE. 2019;14: e0212117.PubMedPubMedCentralCrossRef
23.
Guo A, Jin H, Mao J, Zhu W, Zhou Y, Ge X, Yu D. Impact of health literacy and social support on medication adherence in patients with hypertension: a cross-sectional community-based study. BMC Cardiovasc Disord. 2023;23:93.PubMedPubMedCentralCrossRef
24.
Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial: variation in follow-up for elevated PSA. Cancer. 2013;119:2223–9.PubMedCrossRef
25.
Thotamgari SR, Sheth AR, Grewal US.  Racial disparities in cardiovascular disease among patients with cancer in the United States: The Elephant in the Room. eClinicalMedicine. 2022; 44:101297.
26.
Shi T, Jiang C, Zhu C, Wu F, Fotjhadi I, Zarich S. Insurance disparity in cardiovascular mortality among non-elderly cancer survivors. Cardio-Oncol. 2021;7:11.CrossRef
27.
Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study: Nationwide population-based study on socioeconomic status and prostate cancer. Int J Cancer. 2018;142:2478–84.PubMedPubMedCentralCrossRef
28.
Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncol Williston Park N. 2013;27(80–81):149.
29.
Lentz R, Benson AB, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120:85–92.PubMedCrossRef
30.
31.
Valero-Elizondo J, Chouairi F, Khera R, et al. Atherosclerotic cardiovascular disease, cancer, and financial toxicity among adults in the United States. JACC CardioOncology. 2021;3:236–46.PubMedPubMedCentralCrossRef
32.
Pichardo MS, Minas TZ, Pichardo CM, Bailey-Whyte M, Tang W, Dorsey TH, Wooten W, Ryan BM, Loffredo CA, Ambs S. Association of neighborhood deprivation with prostate cancer and immune markers in African American and European American Men. JAMA Netw Open. 2023;6: e2251745.PubMedPubMedCentralCrossRef
33.
Fowler JE, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol. 1996;156:133–6.PubMedCrossRef
34.
35.
36.
Kubota Y, Heiss G, MacLehose RF, Roetker NS, Folsom AR. Association of educational attainment with lifetime risk of cardiovascular disease: The Atherosclerosis Risk in Communities Study. JAMA Intern Med. 2017;177:1165.PubMedPubMedCentralCrossRef
37.
Zahnd WE, Scaife SL, Francis ML. Health literacy skills in rural and urban populations. Am J Health Behav. 2009;33:550–7.PubMedCrossRef
38.
Addison D, Branch M, Baik AH, et al. Equity in cardio-oncology care and research: a scientific statement from the American Heart Association. Circulation. 2023. CIR.0000000000001158.
39.
Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92–02. J Clin Oncol. 2008;26:4333–9.PubMedPubMedCentralCrossRef
40.
Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056–62.PubMedCrossRef
41.
Feng X, Song M, Preston MA, et al. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. 2020;123:657–65.PubMedPubMedCentralCrossRef
42.
Ling S, Brown K, Miksza JK, Howells L, Morrison A, Issa E, Yates T, Khunti K, Davies MJ, Zaccardi F. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care. 2020;43:2313–22.PubMedCrossRef
43.
Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B, Crawley D. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer. 2020;20:551.PubMedPubMedCentralCrossRef
44.
Sarma AV, Hotaling J, Dunn RL, et al. Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. J Urol. 2015;193:786–93.PubMedCrossRef
45.
Lee J, Hong EM, Kim JH, Jung JH, Park SW, Koh DH, Choi MH, Jang HJ, Kae SH. Metformin induces apoptosis and inhibits proliferation through the AMP-activated protein kinase and insulin-like growth factor 1 receptor pathways in the bile duct cancer cells. J Cancer. 2019;10:1734–44.PubMedPubMedCentralCrossRef
46.
Haring A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51:5–12.PubMedCrossRef
47.
Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami H-O, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012–20.PubMedCrossRef
48.
Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Association between metformin use and risk of prostate cancer and its grade. JNCI J Natl Cancer Inst. 2013;105:1123–31.PubMedCrossRef
49.
Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev. 2011;20:337–44.PubMedCrossRef
50.
He K, Hu H, Ye S, Wang H, Cui R, Yi L. The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. Sci Rep. 2019;9:2218.PubMedPubMedCentralCrossRef
51.
Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184–95.PubMedPubMedCentralCrossRef
52.
Xiao Y, Zheng L, Mei Z, Xu C, Liu C, Chu X, Hao B. The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:100449–58.PubMedPubMedCentralCrossRef
53.
• Ahn HK, Lee YH, Koo KC. Current status and application of metformin for prostate cancer: a comprehensive review (PMID: 33198356; PMCID: PMC7698147). Int J Mol Sci. 2020;21(22):8540. https://​doi.​org/​10.​3390/​ijms21228540. This review article offers an in-depth explorationof the metformin’s anti-cancer mechanisms Itsbalanced perspective captures both the potential benefitsand controversies surrounding metformin’s rolein Prostate cancer.
54.
Hwang IC, Park SM, Shin D, Ahn HY, Rieken M, Shariat SF. Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2015;16:595–600.PubMedCrossRef
55.
Crawley D, Chandra A, Loda M, et al. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer. 2017;17:494.PubMedPubMedCentralCrossRef
56.
Gillessen S, Gilson C, James N, Adler A, Sydes MR, Clarke N, STAMPEDE Trial Management Group. repurposing metformin as therapy for prostate cancer within the STAMPEDE trial platform. Eur Urol. 2016;70:906–8.CrossRef
57.
Tzortzis V, Samarinas M, Zachos I, Oeconomou A, Pisters LL, Bargiota A. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Horm Athens Greece. 2017;16:115–23.
58.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.PubMedCrossRef
59.
Li X-X, Zhang Y-G, Wang D, Chen Y-F, Shan Y-H. Preventive effects of aspirin on cardiovascular complications in prostate cancer cases after endocrinotherapy. Asian Pac J Cancer Prev. 2015;16:4909–13.PubMedCrossRef
60.
61.
Corona G, Filippi S, Bianchi N, Dicuio M, Rastrelli G, Concetti S, Sforza A, Maggi M. Cardiovascular risks of androgen deprivation therapy for prostate cancer. World J Mens Health. 2021;39:429.PubMedCrossRef
62.
Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.PubMedCrossRef
63.
Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8:118–29.PubMedCrossRef
64.
Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE. 2014;9: e107516.PubMedPubMedCentralCrossRef
65.
Gong J, Payne D, Caron J, et al. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer. JACC CardioOncology. 2020;2:553–63.PubMedPubMedCentralCrossRef
66.
Klimis H, Pinthus JH, Aghel N, et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer. JACC CardioOncology. 2023;5:70–81.PubMedPubMedCentralCrossRef
67.
68.
69.
Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst. 2001;49:1–40.
70.
Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217:R47–71.PubMedCrossRef
71.
McEwen BS. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci. 1998;840:33–44.PubMedCrossRef
72.
Moore JX, Bevel MS, Aslibekyan S, Akinyemiju T. Temporal changes in allostatic load patterns by age, race/ethnicity, and gender among the US adult population; 1988–2018. Prev Med. 2021;147: 106483.PubMedPubMedCentralCrossRef
73.
Stabellini N, Cullen J, Moore JX, Cao L, Agarwal N, Hamerschlak N, Waite K, Montero AJ, Barnholtz-Sloan JS, Guha A. Racial differences in chronic stress/allostatic load variation due to androgen deprivation therapy in prostate cancer. JACC CardioOncology. 2022;4:555–7.PubMedPubMedCentralCrossRef
74.
• Stabellini N, Cullen J, Bittencourt MS, et al (2023) Allostatic load and cardiovascular outcomes in males with prostate cancer. JNCI Cancer Spectr 7:pkad005. Findings of this study explain how Allostatic Load can be an indicator for major cardiac events after a PC diagnosis. It sheds light on the importance of considering pre-cancer AL and suggests potential mitigation strategies for high-risk patients.
75.
Morgans AK, Fan K-H, Koyama T, et al. Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol. 2015;193:1226–31.PubMedCrossRef
76.
Hamczyk MR, Nevado RM, Barettino A, Fuster V, Andrés V. Biological versus chronological aging. J Am Coll Cardiol. 2020;75:919–30.PubMedCrossRef
77.
Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis. Clin Epigenetics. 2019;11:62.PubMedPubMedCentralCrossRef
78.
Murabito JM, Zhao Q, Larson MG, Rong J, Lin H, Benjamin EJ, Levy D, Lunetta KL. Measures of biologic age in a community sample predict mortality and age-related disease: The Framingham Offspring Study. J Gerontol Ser A. 2018;73:757–62.CrossRef
79.
Roetker NS, Pankow JS, Bressler J, Morrison AC, Boerwinkle E. Prospective study of epigenetic age acceleration and incidence of cardiovascular disease outcomes in the ARIC Study (Atherosclerosis Risk in Communities). Circ Genomic Precis Med. 2018;11: e001937.CrossRef
80.
Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci. 2003;104:195–201.CrossRef
81.
Cai J-J, Wen J, Jiang W-H, Lin J, Hong Y, Zhu Y-S. Androgen actions on endothelium functions and cardiovascular diseases. J Geriatr Cardiol JGC. 2016;13:183–96.PubMed
82.
Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30:410–5.PubMedCrossRef
83.
Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, Scher HI, Nilsson J, Hultgårdh-Nilsson A. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice. Sci Rep. 2016;6:26220.PubMedPubMedCentralCrossRef
84.
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576–90.PubMedCrossRef
85.
86.
Rubio-Ruiz ME, Peredo-Escárcega AE, Cano-Martínez A, Guarner-Lans V. An evolutionary perspective of nutrition and inflammation as mechanisms of cardiovascular disease. Int J Evol Biol. 2015;2015:1–10.CrossRef
87.
Zhang W, Song M, Qu J, Liu G-H. Epigenetic modifications in cardiovascular aging and diseases. Circ Res. 2018;123:773–86.PubMedCrossRef
88.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.PubMedCrossRef
89.
Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112:25–31.PubMedCrossRef
90.
Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation. 2003;108:2317–22.PubMedCrossRef
91.
92.
Liang KP, Maradit-Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, Gabriel SE. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36:2462–9.PubMedPubMedCentralCrossRef
93.
Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, De Lemos JA. Antinuclear antibodies are associated with all-cause mortality and cardiovascular outcomes in the general population. J Am Coll Cardiol. 2015;65:2669–70.PubMedCrossRef
94.
Folsom AR, Alonso A, George KM, Roetker NS, Tang W, Cushman M. Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Res. 2015;136:781–5.PubMedPubMedCentralCrossRef
95.
96.
97.
98.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH. PRONOUNCE Study Investigators. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295–1307. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​121.​056810. Epub 2021 Aug 30. Erratum in: Circulation. 2021 Oct 19;144(16):e273. PMID: 34459214; PMCID: PMC9004319.
99.
100.
101.
Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider JR, Mucci L, Kantoff PW, Sweeney CJ. Elevated IL-8, TNF-alpha, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate. 2014;74:820–8. https://​doi.​org/​10.​1002/​pros.​22788.CrossRefPubMed
102.
Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC Study. J Urol. 2020;203(6):1109–16. https://​doi.​org/​10.​1097/​JU.​0000000000000714​. Epub 2020 Jan 3 PMID: 31899651.CrossRefPubMed
103.
Metadata
Title
Understanding Cardiovascular Risk in Prostate Cancer: Role of Disparities, Diabetes, and Aging
Authors
Priyanshu Nain, MD
Lakshya Seth, BA
Vraj Patel, BS
Stephanie Jiang, BS
Gaurav Gopu, BS
Rishabh Singh, MD
Nickolas Stabellini, BS
Ritu Reddy, BS
Neal L. Weintraub, MD
Ryan A. Harris, PhD
Jennifer Cullen, PhD, MPH
Neeraj Agarwal, MD
Justin Xavier Moore, PhD, MPH
Nazish Sayed, MD, PhD
Avirup Guha, MD, MPH
Publication date
02-04-2024
Publisher
Springer US
Published in
Current Treatment Options in Cardiovascular Medicine / Issue 5/2024
Print ISSN: 1092-8464
Electronic ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-024-01035-5